Transforming Cancer Care with Radiopharmaceutical Innovation
We are developing
next-generation targeted therapies
for treatment-resistant cancer.
We are developing
next-generation targeted therapies
for treatment-resistant cancer.
Transforming Cancer Care with Radiopharmaceutical Innovation
We are developing
next-generation targeted therapies for treatment-resistant cancer.
Our Mission
Our Mission
Nuclide Therapeutics is pioneering
radiopharmaceutical therapies that unite nuclear medicine with biotechnology.
Our mission is to provide hope and new treatment options for patients with
cancers that have limited alternatives.
Nuclide Therapeutics is pioneering
radiopharmaceutical therapies that unite nuclear medicine with biotechnology.
Our mission is to provide hope and new treatment options for patients with cancers that have limited alternatives.
Technology
Technology
Our technology will bring hope to therapy-resistant patients
For cancers with no effective treatments the need is urgent.
![](data:image/svg+xml,<svg display="block" role="presentation" viewBox="0 0 64 31" xmlns="http://www.w3.org/2000/svg"><g d="M 37.621 5.58 C 39.279 3.379 41.586 1.755 44.216 0.936 C 46.846 0.117 49.667 0.144 52.281 1.013 C 54.896 1.883 57.171 3.551 58.786 5.783 C 60.401 8.015 61.275 10.697 61.284 13.452 C 61.293 16.207 60.437 18.895 58.837 21.138 C 57.237 23.38 54.973 25.064 52.365 25.951 C 49.757 26.838 46.936 26.884 44.3 26.083 C 41.665 25.281 39.347 23.672 37.675 21.483 L 48.129 13.496 Z M 33.003 13.1 L 25.379 13.1 M 45.138 13.603 L 32.751 4.294 L 32.75 22.909 Z M 13.098 0 C 20.332 0 26.196 5.864 26.196 13.098 C 26.196 20.332 20.332 26.196 13.098 26.196 C 5.864 26.196 0 20.332 0 13.098 C 0 5.864 5.864 0 13.098 0 Z M 13.094 10.56 C 14.498 10.56 15.636 11.699 15.636 13.103 C 15.636 14.506 14.498 15.645 13.094 15.645 C 11.69 15.645 10.551 14.506 10.551 13.103 C 10.551 11.699 11.69 10.56 13.094 10.56 Z M 17.402 12.966 C 17.402 12.927 17.411 12.888 17.411 12.849 C 17.411 11.209 16.518 9.796 15.208 9.016 L 19.541 3.407 C 20.945 4.334 22.142 5.615 23.03 7.171 C 23.919 8.726 24.409 10.41 24.493 12.088 L 17.402 12.961 Z M 8.643 12.888 C 8.643 12.917 8.653 12.947 8.653 12.976 L 1.567 12.058 C 1.655 10.375 2.151 8.697 3.044 7.151 C 3.942 5.605 5.149 4.329 6.563 3.407 L 10.866 9.04 C 9.541 9.816 8.643 11.239 8.643 12.883 Z M 10.895 17.033 C 11.533 17.381 12.249 17.597 13.025 17.597 C 13.8 17.597 14.521 17.381 15.154 17.033 L 15.262 17.033 L 18.02 23.643 C 16.519 24.404 14.816 24.806 13.025 24.806 C 11.233 24.806 9.53 24.404 8.029 23.643 L 10.787 17.033 L 10.9 17.033 Z" fill="transparent" height="26.651796468186262px" id="aAXlptr3f" transform="translate(0.681 2.057)" width="61.28403853979703px"><path d="M 0 5.239 C 1.658 3.039 3.964 1.415 6.595 0.595 C 9.225 -0.224 12.046 -0.197 14.66 0.673 C 17.274 1.542 19.549 3.211 21.164 5.442 C 22.779 7.674 23.653 10.357 23.663 13.111 C 23.672 15.866 22.816 18.555 21.216 20.797 C 19.616 23.04 17.352 24.723 14.744 25.61 C 12.135 26.497 9.315 26.543 6.679 25.742 C 4.043 24.94 1.726 23.331 0.053 21.142 L 10.507 13.156 Z" fill="rgb(34, 44, 92)" height="26.31113828032005px" id="OFBec1oBa" transform="translate(37.621 0.341)" width="23.66261291113492px"/><path d="M 7.624 0 L 0 0" fill="transparent" height="1px" id="gesgUWH69" stroke-dasharray="" stroke-linecap="butt" stroke-linejoin="miter" stroke-miterlimit="10" stroke-width="4.09" stroke="rgb(34, 44, 92)" transform="translate(25.379 13.1)" width="7.623751648351572px"/><path d="M 12.389 9.309 L 0.001 0 L 0 18.615 Z" fill="rgb(212, 0, 140)" height="18.615370549450546px" id="Q0VQtQr24" transform="translate(32.75 4.294)" width="12.388553846153854px"/><path d="M 13.098 0 C 20.332 0 26.196 5.864 26.196 13.098 C 26.196 20.332 20.332 26.196 13.098 26.196 C 5.864 26.196 0 20.332 0 13.098 C 0 5.864 5.864 0 13.098 0 Z" fill="rgb(211, 90, 90)" height="26.19611054945055px" id="TcjNmWNZC" stroke-dasharray="" stroke-linecap="butt" stroke-linejoin="miter" stroke-miterlimit="10" stroke-width="1.02" stroke="rgb(107, 43, 43)" transform="translate(0 0)" width="26.19613098901118px"/><path d="M 2.542 0 C 3.946 0 5.084 1.138 5.084 2.542 C 5.084 3.946 3.946 5.084 2.542 5.084 C 1.138 5.084 0 3.946 0 2.542 C 0 1.138 1.138 0 2.542 0 Z" fill="rgb(107, 43, 43)" height="5.084136263736269px" id="Z3Q2wzZ5p" transform="translate(10.551 10.56)" width="5.084204395604502px"/><path d="M 2.194 9.56 C 2.194 9.52 2.203 9.481 2.203 9.442 C 2.203 7.803 1.31 6.39 0 5.609 L 4.333 0 C 5.737 0.928 6.934 2.208 7.823 3.764 C 8.711 5.32 9.202 7.003 9.285 8.681 L 2.194 9.555 Z" fill="rgb(107, 43, 43)" height="9.559780000000003px" id="qvtBLkUvx" transform="translate(15.208 3.407)" width="9.284949670329752px"/><path d="M 7.077 9.481 C 7.077 9.511 7.086 9.54 7.086 9.57 L 0 8.652 C 0.088 6.969 0.584 5.29 1.477 3.744 C 2.375 2.199 3.582 0.923 4.996 0 L 9.3 5.634 C 7.975 6.409 7.077 7.832 7.077 9.476 Z" fill="rgb(107, 43, 43)" height="9.56960461538462px" id="ge_OWZxjd" transform="translate(1.567 3.407)" width="9.299659340659218px"/><path d="M 2.866 0 C 3.504 0.348 4.22 0.564 4.996 0.564 C 5.771 0.564 6.493 0.348 7.126 0 L 7.234 0 L 9.992 6.61 C 8.49 7.371 6.787 7.773 4.996 7.773 C 3.205 7.773 1.502 7.371 0 6.61 L 2.758 0 L 2.871 0 Z" fill="rgb(107, 43, 43)" height="7.773437362637367px" id="n5mRf_oPL" transform="translate(8.029 17.033)" width="9.991606593406686px"/></g></svg>)
![](data:image/svg+xml,<svg display="block" role="presentation" viewBox="0 0 65 29" xmlns="http://www.w3.org/2000/svg"><path d="M 22.442 4.914 C 20.87 2.85 18.682 1.327 16.188 0.558 C 13.693 -0.21 11.017 -0.185 8.538 0.631 C 6.059 1.447 3.901 3.012 2.369 5.105 C 0.838 7.199 0.009 9.715 0 12.299 C -0.009 14.883 0.803 17.405 2.321 19.508 C 3.838 21.612 5.985 23.191 8.459 24.023 C 10.933 24.855 13.608 24.898 16.108 24.146 C 18.607 23.394 20.805 21.885 22.392 19.832 L 12.477 12.34 Z" fill="rgb(34, 44, 92)" height="24.680453708862263px" id="WsNhFTkIH" transform="translate(1 2.68)" width="22.442069825869567px"/><path d="M 0 0 L 7.231 0" fill="transparent" height="1px" id="PXroenN3M" stroke-dasharray="" stroke-linecap="butt" stroke-linejoin="miter" stroke-miterlimit="10" stroke-width="3.88" stroke="rgb(34, 44, 92)" transform="translate(31.693 14.503)" width="7.230510318954998px"/><path d="M 0 8.732 L 11.748 0 L 11.75 17.462 Z" fill="rgb(212, 0, 140)" height="17.461646327277176px" id="UjY2a114P" transform="translate(20.062 6.514)" width="11.749538882330967px"/><path d="M 12.422 0 C 5.562 0 0 5.501 0 12.286 C 0 19.072 5.562 24.573 12.422 24.573 C 19.283 24.573 24.845 19.072 24.845 12.286 C 24.845 5.501 19.283 0 12.422 0 Z" fill="rgb(117, 174, 105)" height="24.572555047971427px" id="QeKUvLOUj" stroke-dasharray="" stroke-linecap="butt" stroke-linejoin="miter" stroke-miterlimit="10" stroke-width="0.97" stroke="rgb(21, 92, 13)" transform="translate(38.155 2.36)" width="24.844906309833732px"/><path d="M 2.411 0 C 1.079 0 0 1.068 0 2.385 C 0 3.701 1.079 4.769 2.411 4.769 C 3.743 4.769 4.822 3.701 4.822 2.385 C 4.822 1.068 3.743 0 2.411 0 Z" fill="rgb(21, 92, 13)" height="4.7690369139424575px" id="FdDCVL8T6" transform="translate(48.171 12.266)" width="4.821955651459689px"/><path d="M 6.726 8.967 C 6.726 8.93 6.716 8.894 6.716 8.857 C 6.716 7.319 7.563 5.994 8.806 5.262 L 4.696 0 C 3.365 0.87 2.229 2.071 1.387 3.531 C 0.545 4.99 0.079 6.569 0 8.143 L 6.726 8.963 Z" fill="rgb(21, 92, 13)" height="8.967293822228253px" id="nRShkh8fv" transform="translate(39.771 5.555)" width="8.806021955976462px"/><path d="M 2.108 8.894 C 2.108 8.921 2.099 8.949 2.099 8.977 L 8.82 8.116 C 8.736 6.537 8.266 4.962 7.419 3.512 C 6.567 2.062 5.422 0.865 4.082 0 L 0 5.285 C 1.257 6.012 2.108 7.347 2.108 8.889 Z" fill="rgb(21, 92, 13)" height="8.976509537740977px" id="ZEk3XmSax" transform="translate(52.694 5.555)" width="8.819972885651396px"/><path d="M 6.758 0 C 6.153 0.327 5.473 0.529 4.738 0.529 C 4.003 0.529 3.318 0.327 2.718 0 L 2.616 0 L 0 6.201 C 1.424 6.914 3.039 7.292 4.738 7.292 C 6.437 7.292 8.052 6.914 9.476 6.201 L 6.86 0 L 6.753 0 Z" fill="rgb(21, 92, 13)" height="7.291663285081498px" id="AtyPvf9ye" transform="translate(45.909 18.337)" width="9.476228753094915px"/></svg>)
Technology
Our technology will bring hope to therapy-resistant patients
For cancers with no effective treatments the need is urgent.
Our Pipeline
Our lead diagnostic and therapeutic programs are progressing through preclinical evaluation and first-in-human studies.
About
About
Bringing together experts in radiopharmaceutical development
Led by a multidisciplinary founding team combining decades of experience across chemistry, molecular biology, and radiopharmaceutical innovation:
About
Bringing together experts in radiopharmaceutical development
Led by a multidisciplinary founding team combining decades of experience across chemistry, molecular biology, and radiopharmaceutical innovation:
News
News
Stay up to date with the latest from NuclideTx
From research breakthroughs and company milestones to opportunities to develop your career as we shape the future of radionuclide therapy.
Oct 8, 2025
Latest press release
Read our press release detailing the conclusion of our recent funding round.
Oct 8, 2025
Latest press release
Read our press release detailing the conclusion of our recent funding round.
Oct 8, 2025
Latest press release
Read our press release detailing the conclusion of our recent funding round.
Sep 22, 2025
Launch announcement
Nuclide Therapeutics secures £5 million investment to spearhead first-in-human clinical trials.
Sep 22, 2025
Launch announcement
Nuclide Therapeutics secures £5 million investment to spearhead first-in-human clinical trials.
Sep 22, 2025
Launch announcement
Nuclide Therapeutics secures £5 million investment to spearhead first-in-human clinical trials.
Connect with us
Email us, and keep updated on our clinical trial pipeline on LinkedIn.
Connect with us
Email us, and keep updated on our clinical trial pipeline on LinkedIn.
© 2025 Nuclide Therapeutics, All rights reserved
© 2025 Nuclide Therapeutics, All rights reserved
© 2025 Nuclide Therapeutics, All rights reserved